PIM-1 kinase: a potential biomarker of triple-negative breast cancer

Jieying Chen, Guangyu TangDepartment of Radiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaAbstract: Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagno...

Full description

Bibliographic Details
Main Authors: Chen J, Tang G
Format: Article
Language:English
Published: Dove Medical Press 2019-08-01
Series:OncoTargets and Therapy
Subjects:
Online Access:https://www.dovepress.com/pim-1-kinase-a-potential-biomarker-of-triple-negative-breast-cancer-peer-reviewed-article-OTT
Description
Summary:Jieying Chen, Guangyu TangDepartment of Radiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaAbstract: Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagnosis and treatment are lacking. The tumorigenicity of the provirus integration site for Moloney murine leukemia virus 1 (PIM-1) gene has been studied for many years. However, its significance in breast cancer remains unclear. In this review we briefly summarized the physiological characteristics and regulation of PIM-1 kinase, and subsequently focused on the role of PIM-1 in tumors, especially breast cancer. Oncogene PIM-1 was found to be upregulated in breast cancer, especially in triple-negative breast cancer. Moreover, it is involved in tumorigenesis and the development of drug resistance, and linked to poor prognosis. A highly selective probe targeting PIM-1 for imaging has emerged, suggesting that PIM-1 may be a potential biomarker for the accurate diagnosis and targeted therapy of triple-negative breast cancer.Keywords: triple-negative breast cancer, biomarker, PIM-1
ISSN:1178-6930